Prostate cancer: immunotherapy offers hope

(Medical University of Vienna) An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer. This is the finding of the long-term analyses of an international phase 3 clinical trial, recently published in the leading journal " European Urology " . The study showed that overall survival was 2 - 3 times higher than in the placebo arm.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news